Psoriasis: risankizumab tops secukinumab in year-long, open-label trial

  • Warren RB & al.
  • Br J Dermatol
  • 28 Jun 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Risankizumab is associated with better efficacy and similar safety compared with secukinumab for moderate to severe plaque psoriasis.
  • These results are from to a 52-week, phase 3, randomized, open-label, efficacy assessor-blinded clinical trial.

Why this matters

  • The availability of novel psoriasis treatments necessitates head-to-head trials.
  • Risankizumab requires less frequent dosing compared with secukinumab.

Key results

  • At week 16, risankizumab was noninferior to secukinumab for rates of ≥90% improvement in the Psoriasis Area Severity Index (PASI 90): 73.8% vs 65.6%.
  • At 52 weeks, risankizumab was associated with a superior PASI 90 rate compared with secukinumab: 86.6% vs 57.1% (P<.001 style="list-style-type:circle;">
  • Risankizumab was also superior for rates of PASI 75, PASI 100, and a static Physician Global Assessment score of 0 or 1 (P<.001 for all>
  • Treatment-emergent adverse events were reported for 71.3% of patients treated with risankizumab and 71.2% of patients treated with secukinumab.
  • Serious adverse events were reported for 5.5% of patients treated with risankizumab and 3.7% treated with secukinumab.
  • Study design

    • 327 patients with chronic, moderate to severe plaque psoriasis were randomly assigned to receive risankizumab 150 mg (n=164) or secukinumab 300 mg (n=163), and efficacy and safety were assessed over 52 weeks.
    • Funding: AbbVie.

    Limitations

    • Open-label design.